Abingdon-based Sense says the self-contained, single-use Veros product platform can deliver lab-quality results in 15 minutes.
Una is a leading specialty medical distributor focused on improving outcomes at the point-of-care and is well-known for its ability to cultivate new markets with innovative technology.
Sense says the agreement with Una is the first in a series of expected announcements in anticipation of regulatory approvals.
“Una is an ideal commercial partner because of its exceptional experience in launching new products and creating opportunities for improved patient care,” said Ryan Roberts, chief commercial officer at Sense.
“Una’s strong relationships with customers in the point-of-care segment will be well served by the benefits that our rapid Veros Covid-19 can bring to the healthcare delivery process, providing the confidence of lab-quality results wherever they are needed.
“We look forward to working with Una as we introduce the first Veros branded products to the market.”
Fiona Jacobs, managing director of Una Health, said: “Being able to offer our customers an instrument-free, lab-quality result in minutes and at the point-of-care is exactly the kind of product that reflects our ethos of delivering product offerings that improve operational, clinical and economic outcomes in the healthcare system.
“As the coronavirus continues to significantly impact all aspects of society, Veros Covid-19 is a powerful tool to help us return to our normal lives.”
Veros has the potential to be the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results within 15 minutes.
Unconstrained by an instrument or reader, the Veros platform can help to improve access to rapid, highly accurate, point of care testing for many more people.